Cross-reactivity of the CEDIA buprenorphine assay with opiates: an Austrian phenomenon?
When testing the Microgenics CEDIA assay for immunological buprenorphine analysis, cross-reactivity between the buprenorphine reagents and opiates was observed at concentrations higher than 120 mg/l morphine, 320 mg/l methadone, 30 mg/l codeine, 60 mg/l dihydrocodeine and 520 mg/l morphine-3-glucuronide. The cross-reactivity with morphine has the greatest impact on routine screening as opiate maintenance therapy in Austria is also performed with slow-release oral morphine. The use of a second cutoff value of 30 mug/l for urine samples that are (immunologically) positive for opiates is therefore suggested, compared to the cutoff value of 5 microg/l proposed by the manufacturer.
Pavlic
M
M
Institute of Legal Medicine, Innsbruck Medical University, Muellerstrabe 44, 6020 Innsbruck, Austria. marion.pavlic@uibk.ac.at
Libiseller
K
K
Grubwieser
P
P
Rabl
W
W
D001317:Austria; D002047:Buprenorphine / Q000276:immunology / Q000627:therapeutic use / Q000652:urine*; D003429:Cross Reactions; D006801:Humans; D007118:Immunoassay; D016014:Linear Models; D009292:Narcotic Antagonists / Q000276:immunology / Q000627:therapeutic use / Q000652:urine*; D009294:Narcotics / Q000652:urine*; D009293:Opioid-Related Disorders / Q000534:rehabilitation; D012189:Retrospective Studies
D009292:Narcotic Antagonists; D009294:Narcotics; D002047:Buprenorphine